Multikinase inhibitors
https://themeditary.com/dosage-information/sotyktu-dosage-5319.html

Sotyktu Dosage

Drug Detail:Sotyktu (Deucravacitinib)

Generic Name: DEUCRAVACITINIB 6mg

Dosage Form: tablet, film coated

Drug Class: Multikinase inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Recommended Evaluations and Immunizations Prior to Treatment Initiation

Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU. If positive, start treatment for TB prior to SOTYKTU use [see Warnings and Precautions (5.3)].

Update immunizations according to current immunization guidelines [see Warnings and Precautions (5.7)].

Recommended Dosage

The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.

Do not crush, cut, or chew the tablets.

Recommended Dosage in Patients with Hepatic Impairment

SOTYKTU is not recommended in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

No dosage adjustment is needed for patients with mild to moderate hepatic impairment.

Share this Article
Latest News
Related Drugs